A new test to detect antibodies that fight HIV
Official title: Ultrasensitive Env Detection Assay for Broadly Neutralizing Antibody Screening
Funded at George Washington University · NIH-11060970 · Data updated 2026-11-12
This study is working on a new, super-sensitive test to find important antibodies in people with HIV-1, which could help doctors create better and more personalized treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | April 12, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $493,865 |
| NIH project number | 5R61AI176582-03 |
| Project ID | NIH-11060970 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who may benefit from new immunotherapy approaches.
✕Less likely to help
Patients who are not living with HIV or those who do not have detectable levels of antibodies may not benefit from this research.
What this research studies
This research focuses on developing an ultrasensitive assay to detect broadly neutralizing antibodies (bNAbs) against HIV-1, which are crucial for effective immunotherapy. The study aims to overcome challenges in current testing methods by providing quicker results and using samples directly from patients. By optimizing the detection of these antibodies in blood plasma and cell lysates, the research seeks to improve the pre-screening process for clinical trials, ultimately enhancing treatment strategies for HIV-1. Patients may benefit from more personalized and effective treatment options based on their specific antibody responses.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate identification of effective HIV treatments for patients.
How similar studies have gone: Previous research has shown promise in developing similar antibody detection methods, indicating potential for success in this novel approach.
Where this research is happening
-
George Washington University
Washington, United States Active
Researchers
- Principal investigator: Lynch, Rebecca Marie — George Washington University
- Study coordinator: Lynch, Rebecca Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.